Navigation Links
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Date:10/26/2009

alon's business and the effect on Cephalon's long-term growth of biologic products and the possible acquisition of BDC, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion

    Contacts:

    Cephalon:
    Media:                             Investor Relations:
    Sheryl Williams                    Chip Merritt
    610-738-6493 (office)              610-738-6376 (office)
    610-457-5257 (cell)                cmerritt@cephalon.com
    swilliam@cephalon.com

    BDC:
    Media:                             Investors:
    Douglas MacDougall     
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/24/2015)... The first step to transforming one’s life ... meditation and yoga teacher Stine Koppernæs, meditation and changing ... that allow her to experience more peace and freedom ... teacher since 2006, and through the years she has ... , “I love sharing this way of finding true, ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Anchor Health ... Medical Field Professionals, today announced their exclusive agreement with ... Long Term Care Insurance distribution partner. , Anchor has ... Term Care Insurance benefits for associations, and is currently ... its Long Term Care Insurance member benefit. , ...
(Date:4/24/2015)... 24, 2015 “Kind,” “selfless,” “the voice ... the ways Denise Weiner described pediatric oncology nurse Laura ... her daughter, Alexa, during her five-year battle with a ... bone marrow transplant and numerous experimental treatments, Vasquez continued ... Alexa when she was not in the hospital and ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... MA (PRWEB) April 24, 2015 ... prime location for patients looking to enroll in ... is less than a mile away from Alternative ... is scheduled to open this summer. With ... to be the go-to place for residents of ...
Breaking Medicine News(10 mins):Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Medical Doctor from Salem Massachusetts Supports the Medical Marijuana Industry 2
... towards food has cost us a fortune as no one really ... dedicated university researcher spent part of his lifetime organizing his students ... waste at every stage along the food chain. His findings have ... ever eaten. ,Studies have show that in agriculture, where ...
... A protein that protects the body from tissue damage has ... protein helps the body's healthy cells survive the effects of ... found to encourage the growth of tumors in mice following ... urethane, a lung-specific carcinogen, on two sets of mice, which ...
... More people in the West are turning to yoga now to ... provides a good feeling and enormous satisfaction," Kumud Schramm of the ... regularly you become more alert and are not thrown out of ... Frankfurt. , ,For the past two years, there has been ...
... for Cellular and Molecular Biology (CCMB), Hyderabad has unraveled ... detecting the mechanisms that prevent cancer in human beings//. ... Bhadra have been instrumental behind this novel finding to ... for centuries. ,They hope that silencing segments of ...
... being investigated to find out how effectively it can be ... successful, it might turn out to be an ideal alternative ... ,It has been a problem of concern as regarding what ... therapy. This study has been initiated taking into account the ...
... study that is published in the current issue of ... that make popcorn are at a heightened health risk ... WV, Bethesda, MD, and San Francisco, CA, administered a ... employed by a popcorn factory. , ,Fifty-nine workers ...
Cached Medicine News:
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... The Criterion Dodeca cell, a component of ... run up to 12 Criterion gels in a ... (13.3 x 8.7 cm) than the traditional mini ... strips to give you the optimal combination of ...
... Dodeca cell accommodates up to 12 large ... runs in the PROTEAN IEF system, for ... The PROTEAN Plus Dodeca cell's cooling and ... allow consistent, high-resolution results. The handcasting system ...
... ElectroXpress gel electrophoresis system mirrors a 96-well ... screening of PCR products to take place ... source (96-well) plate. Loading can be carried out ... first time in the industry two sets ...
Medicine Products: